Abstract
Purpose
To identify preference of treatment regimen in patients with anti-VEGF therapy for neovascular age-related macular degeneration (AMD) in real life.
Methods
A cross-sectional study was conducted in 200 patients receiving ranibizumab therapy on a pro re nata regimen with monthly controls. One hundred and twenty-four patients were recruited in a tertiary health care clinic, and 76 patients were recruited in a private practice. Patients were asked to respond to a 14-item questionnaire covering items such as treatment burden and preference for treatment: either monthly injections or pro re nata.
Results
Mean time under anti-VEGF treatment was 33.7 months, and the mean number of intravitreal injections was 17.7. Despite a high treatment burden in 60.3 % of patients, there was an acceptance rate for monthly examinations or injections of 93 %. The proportion of patients who favoured a PRN regimen was 53.0 %, whereas 37.9 % of patients favoured continuous injections. Major concern was recurrent disease activity in 54.5 %.
Conclusion
We identified two groups of patients of considerable size who would prefer either monthly injections or as-required. Overall, there was a high acceptance rate despite a high treatment burden. Nevertheless, efforts should be undertaken to improve examination and injection procedures and to consider the patient’s preference for a treatment regimen.
Similar content being viewed by others
References
Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398
Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150:315–324
Droege KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchhof B, Fauser S (2012) Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol 251(5):1281–1284. doi:10.1007/s00417-012-2177-3
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411
Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S (2012) Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:453–458
Financial disclosure
No author has any financial interests.
Author information
Authors and Affiliations
Corresponding author
Additional information
Authors have full control of all primary data, and agree to allow Graefe's Archive for Clinical and Experimental Ophthalmology to review the data upon request.
Rights and permissions
About this article
Cite this article
Droege, K.M., Caramoy, A., Kersten, A. et al. Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration — monthly injections versus pro re nata. Graefes Arch Clin Exp Ophthalmol 252, 31–34 (2014). https://doi.org/10.1007/s00417-013-2412-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-013-2412-6